research News

Toyoake, Japan – Cervical cancer is a highly prevalent cancer, with approximately 500,000 new cases diagnosed each year. Shockingly, the number of individuals diagnosed with precursor lesions in the cervix—also known as cervical intraepithelial neoplasia (CIN)—is 20 times higher. As with many potentially malignant conditions, early diagnosis of cervical cancer...
New York, NY — Advancium Health Network, a public charity dedicated to advancing therapies for rare diseases, has awarded two major grants to accelerate research into a potential treatment for Autosomal Dominant Optic Atrophy (ADOA)—the most common hereditary optic neuropathy. Caused by mutations in the OPA1 gene, ADOA leads to...
Cambridge, Mass. – Rare disease company Agios Pharmaceuticals reached the primary endpoint in a Phase III study for its drug pyrukynd (mitapivat) in adults with non-transfusion-dependent alpha- or beta-thalassemia, according to the company’s announcement on Wednesday The Phase III ENERGIZE study met the primary endpoint of hemoglobin response, defined as...
Changchun, China – Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is a major global health concern with rising rates, particularly in North Africa and East Asia. Although potentially curable in the early stages, HCC often remains undetected until it’s too late for effective treatment. This...
Palo Alto, Calif. – Using novel machine learning tools developed at Stanford Medicine, researchers have mapped three distinct cellular configurations that correspond to clinical outcomes for patients with a rare, difficult-to-treat cancer called soft tissue sarcoma. In particular, the technique identified a cellular neighborhood that correlated with a positive response...